• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's Pre-Market Session

    1/19/23 8:06:03 AM ET
    $APGN
    $ARDX
    $HYPR
    $OLK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $APGN alert in real time by email

    Gainers

    • Apexigen (NASDAQ:APGN) shares moved upwards by 39.7% to $2.5 during Thursday's pre-market session. The company's market cap stands at $56.4 million.
    • Hyperfine (NASDAQ:HYPR) shares increased by 14.75% to $1.01. The company's market cap stands at $71.2 million.
    • Tricida (NASDAQ:TCDA) stock rose 13.2% to $0.16. The company's market cap stands at $9.0 million.
    • Sonnet BioTherapeutics (NASDAQ:SONN) shares increased by 11.91% to $1.41. The company's market cap stands at $11.1 million.
    • Zymeworks BC (NASDAQ:ZYME) stock moved upwards by 11.5% to $11.15. The market value of their outstanding shares is at $702.4 million.
    • RenovoRx (NASDAQ:RNXT) stock rose 9.58% to $4.0. The company's market cap stands at $36.3 million.

    Losers

    • Olink Holding (NASDAQ:OLK) stock fell 14.8% to $20.49 during Thursday's pre-market session. The market value of their outstanding shares is at $2.4 billion.
    • Ontrak (NASDAQ:OTRK) shares fell 14.29% to $0.96. The company's market cap stands at $25.9 million.
    • Ardelyx (NASDAQ:ARDX) stock declined by 13.67% to $2.78. The company's market cap stands at $521.1 million.
    • Surmodics (NASDAQ:SRDX) shares fell 12.97% to $32.5. The company's market cap stands at $459.0 million.
    • TC BioPharm (Holdings) (NASDAQ:TCBP) stock fell 12.23% to $5.53. The company's market cap stands at $219.8 million.
    • Sigilon Therapeutics (NASDAQ:SGTX) stock fell 11.68% to $0.48. The company's market cap stands at $15.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $APGN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APGN
    $ARDX
    $HYPR
    $OLK

    CompanyDatePrice TargetRatingAnalyst
    Ardelyx Inc.
    $ARDX
    1/9/2026Neutral → Overweight
    Piper Sandler
    Zymeworks Inc.
    $ZYME
    12/12/2025$33.00Equal Weight → Overweight
    Wells Fargo
    Zymeworks Inc.
    $ZYME
    12/3/2025$32.00Mkt Outperform
    Citizens JMP
    Surmodics Inc.
    $SRDX
    11/14/2025Mkt Perform → Underperform
    Barrington Research
    Zymeworks Inc.
    $ZYME
    10/24/2025$15.00Equal Weight
    Wells Fargo
    Zymeworks Inc.
    $ZYME
    10/14/2025$26.00Neutral → Buy
    H.C. Wainwright
    Zymeworks Inc.
    $ZYME
    10/10/2025$30.00Buy
    B. Riley Securities
    Ardelyx Inc.
    $ARDX
    9/3/2025$14.00Strong Buy
    Raymond James
    More analyst ratings

    $APGN
    $ARDX
    $HYPR
    $OLK
    SEC Filings

    View All

    SEC Form S-8 filed by Zymeworks Inc.

    S-8 - Zymeworks Inc. (0001937653) (Filer)

    3/2/26 7:23:59 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zymeworks Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Regulation FD Disclosure

    8-K - Zymeworks Inc. (0001937653) (Filer)

    3/2/26 6:28:54 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Zymeworks Inc.

    10-K - Zymeworks Inc. (0001937653) (Filer)

    3/2/26 6:28:07 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APGN
    $ARDX
    $HYPR
    $OLK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Hyperfine, Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026

    Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced that it will report financial results for the fourth quarter and full year 2025 on Wednesday, March 18, 2026. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A live audio webcast and an archive of the recording will be available through the Investors page of Hyperfine, Inc.'s corporate website at https://investors.hyperfine.io/. Participants are encouraged to register more than 15 minutes before the start of the call. F

    3/5/26 4:05:00 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Ardelyx to Participate in Upcoming Investor Conferences

    WALTHAM, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced its participation in the following upcoming investor conferences: Leerink Partners 2026 Global Healthcare ConferenceLocation: Miami, FLPresentation: Tuesday, March 10 at 4:20 p.m. ET1x1 Meetings: Tuesday, March 10 To access the live webcast of the Leerink presentation, please visit the Events and Presentations page within the Ardelyx website at ir.ardelyx.com. A replay of the panel presentation will be available on the Ardelyx website for 30 days follo

    3/4/26 8:00:00 AM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing

    Zymeworks to receive $250 million under a royalty-backed note financing from Royalty Pharma with repayments due from 30% of worldwide tiered royalties on Ziihera until fully repaidZymeworks to retain 70% of royalties on Ziihera sales per the agreement, with full royalty rights reverting to Zymeworks once the royalty payments to Royalty Pharma have ceasedProceeds strengthen Zymeworks' balance sheet with non-dilutive capital and support its stock repurchase program, potential strategic acquisitions, and cash runway beyond 2028 NEW YORK and VANCOUVER, British Columbia, March 02, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) and Zymeworks Inc. (NASDAQ:ZYME) today announced an agre

    3/2/26 6:10:00 AM ET
    $RPRX
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APGN
    $ARDX
    $HYPR
    $OLK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mott David M bought $1,946,331 worth of shares (333,333 units at $5.84), increasing direct ownership by 11% to 3,302,918 units (SEC Form 4)

    4 - ARDELYX, INC. (0001437402) (Issuer)

    2/23/26 9:01:11 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Agah Ramtin bought $9,975 worth of shares (10,000 units at $1.00), increasing direct ownership by 1% to 798,460 units (SEC Form 4)

    4 - RenovoRx, Inc. (0001574094) (Issuer)

    1/22/26 7:00:18 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Agah Ramtin bought $8,424 worth of shares (9,795 units at $0.86), increasing direct ownership by 1% to 788,460 units (SEC Form 4)

    4 - RenovoRx, Inc. (0001574094) (Issuer)

    1/5/26 7:00:02 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APGN
    $ARDX
    $HYPR
    $OLK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Ardelyx upgraded by Piper Sandler

    Piper Sandler upgraded Ardelyx from Neutral to Overweight

    1/9/26 8:23:44 AM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zymeworks upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded Zymeworks from Equal Weight to Overweight and set a new price target of $33.00

    12/12/25 8:37:46 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citizens JMP initiated coverage on Zymeworks with a new price target

    Citizens JMP initiated coverage of Zymeworks with a rating of Mkt Outperform and set a new price target of $32.00

    12/3/25 8:41:52 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APGN
    $ARDX
    $HYPR
    $OLK
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for XPHOZAH issued to ARDELYX INC

    Submission status for ARDELYX INC's drug XPHOZAH (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated

    10/20/23 4:37:52 AM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for XPHOZAH issued to ARDELYX INC

    Submission status for ARDELYX INC's drug XPHOZAH (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Labeling

    10/18/23 4:43:04 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for XPHOZA™ issued to ARDELYX INC

    Submission status for ARDELYX INC's drug XPHOZA™ (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Labeling

    10/18/23 4:37:08 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APGN
    $ARDX
    $HYPR
    $OLK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Raab Michael exercised 20,833 shares at a strike of $0.99 and sold $260,621 worth of shares (41,666 units at $6.25), decreasing direct ownership by 1% to 1,836,153 units (SEC Form 4)

    4 - ARDELYX, INC. (0001437402) (Issuer)

    2/25/26 4:13:00 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Mott David M bought $1,946,331 worth of shares (333,333 units at $5.84), increasing direct ownership by 11% to 3,302,918 units (SEC Form 4)

    4 - ARDELYX, INC. (0001437402) (Issuer)

    2/23/26 9:01:11 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Bishop John E sold $18,586 worth of shares (3,179 units at $5.85), decreasing direct ownership by 0.93% to 339,151 units (SEC Form 4)

    4 - ARDELYX, INC. (0001437402) (Issuer)

    2/23/26 8:54:33 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APGN
    $ARDX
    $HYPR
    $OLK
    Leadership Updates

    Live Leadership Updates

    View All

    RenovoRx Advancing RenovoCath® Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum

    Over the past year, RenovoRx has Tripled Commercially Active U.S. Cancer Centers and Centers Requesting Access to RenovoCath, its FDA-Cleared Device Over 700 RenovoCath Procedures Successfully Completed Since FDA Clearance in 2014 Company Appoints Ramtin Agah, MD to the Additional Position of Executive Chairman to Support Continued Clinical Adoption and Commercial Growth MOUNTAIN VIEW, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced continued commercial progress, with

    2/27/26 8:30:00 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer

    MOUNTAIN VIEW, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, is pleased to announce the appointment of Mark Voll as the Company's Chief Financial Officer, effective February 1, 2026. Mr. Voll brings more than three decades of financial leadership experience to RenovoRx, with a strong track record for guiding high-growth public companies through periods of commercial buildout and strategic development. He has served as Chief Financial Officer for multiple publicly traded technology co

    2/5/26 8:30:00 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pulse Biosciences, Inc. Appoints Maria Sainz to its Board of Directors

    Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced the appointment of Maria Sainz to its Board of Directors effective as of January 9, 2026. "We are delighted to welcome Maria to our Board of Directors," said Pulse Biosciences' Co-Chairman of the Board Robert W. Duggan. "She brings an exceptionally strong track record of guiding both public and private medical device companies through growth, commercialization, viability, and scale. Her strategic and operational expertise will be invaluable as Pulse begins creating and disrupting interventional m

    1/9/26 7:00:00 AM ET
    $AVNS
    $HYPR
    $OFIX
    Industrial Specialties
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Medical/Dental Instruments

    $APGN
    $ARDX
    $HYPR
    $OLK
    Financials

    Live finance-specific insights

    View All

    Hyperfine, Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026

    Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced that it will report financial results for the fourth quarter and full year 2025 on Wednesday, March 18, 2026. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A live audio webcast and an archive of the recording will be available through the Investors page of Hyperfine, Inc.'s corporate website at https://investors.hyperfine.io/. Participants are encouraged to register more than 15 minutes before the start of the call. F

    3/5/26 4:05:00 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

    Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) to be completed by our partner Jazz in first-line HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA) during 1Q 2026 in the U.S. with potential launch in 2H 2026Up to $440.0 million in milestone payments eligible to be earned related to regulatory approvals of Ziihera in GEA in the U.S., Europe, Japan, and ChinaAdditional clinical data for pasritamig in prostate cancer presented at ASCO-GU in February 2026 by Johnson & Johnson Innovative Medicine (J&J)$62.5 million utilized for share repurchases as of March 2, 2026 under the current authorized share repurchase program$250.0 million non-recourse royalty-backed

    3/2/26 6:00:00 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ardelyx Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    IBSRELA revenue grew 73% in 2025 to $274.2 million and total revenues reached $407.3 million Patient-first XPHOZAH strategy preserved access and drove growth in total dispenses Development programs for new IBSRELA indication and next-generation NHE3 inhibitor launched Company is well capitalized to meet current business objectives Conference call scheduled for 4:30 PM Eastern Time WALTHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today reported financial results for the fourth quarter and full year

    2/19/26 4:01:00 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APGN
    $ARDX
    $HYPR
    $OLK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Zymeworks Inc.

    SC 13G/A - Zymeworks Inc. (0001937653) (Subject)

    11/14/24 9:00:57 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by TC BioPharm (Holdings) plc

    SC 13G/A - TC BioPharm (Holdings) plc (0001872812) (Subject)

    11/14/24 4:41:42 PM ET
    $TCBP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Zymeworks Inc.

    SC 13G/A - Zymeworks Inc. (0001937653) (Subject)

    11/14/24 4:27:20 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care